Xeris Biopharma Holdings, Inc.

XERS

HealthcareSmall CapUS Equities · NYSE / NASDAQ

AI Agents

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Valuation

Market Cap$1.0B

Current Price$6.02

P/E Ratio-

P/B Ratio73.41

EV / EBITDA31.98

EV / Sales4.06

Profitability

Operating Margin-

Net Profit Margin0.2%

EBITDA Margin14.5%

Returns

ROE4.0%

ROCE-

ROIC %18.4%

ROA0.1%

Solvency

Current Ratio2.19

Debt / Equity18.85

Debt / Assets0.67

CFO / Net Profit51.67

Price History▲ 36.51% over 1Y

Technical Chart

Historical Performance Charts

5-year financial trends. Figures in USD millions.

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Latest fiscal year: 2025

Revenue$292M▲ 43.7%

EBITDA$42M

Net Profit$1M

Cash from Ops (CFO)$29M

Free Cash Flow (FCF)$28M

Revenue CAGR 3Y-

Revenue CAGR 5Y-

Net Profit CAGR 3Y-

Net Profit CAGR 5Y-

Historical Growth

Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)

Year	Revenue	EBITDA	Net Profit	FCF	ROE	Rev Growth 1Y	NP Growth 1Y
2025	$292M	$42M	$1M	$28M	4.0%	43.7%	-
2024	$203M	$-14M	$-55M	$-38M	185.2%	23.9%	-
2023	$164M	$-24M	$-62M	$-49M	917.9%	48.7%	-
2022	$110M	$-69M	$-95M	$-103M	-209.5%	-	-

Financial Statements

Income statement, balance sheet, and cash flow as reported

Consolidated Figures in USD Millions.

Metric	2022	2023	2024	2025
Total Revenue	110.25	163.91	203.07	291.85
Cost Of Revenue	22.63	28.64	36.83	42.57
Gross Profit	87.61	135.27	166.24	249.28
Operating Expense	169.55	179.28	199.88	224.38
Operating Income	-81.94	-44.01	-33.65	24.90
EBITDA	-69.31	-23.73	-13.99	42.33
EBIT	-81.98	-36.90	-26.62	29.64
Pretax Income	-96.08	-63.50	-57.10	0.55
Tax Provision	-1.42	-1.25	-2.27	0
Net Income	-94.66	-62.26	-54.84	0.55
Net Income Common Stockholders	-94.66	-62.26	-54.84	0.55
Total Expenses	192.19	207.92	236.72	266.95
Interest Expense	14.10	26.61	30.48	29.08
Interest Income	2.58	4.75	5.32	4.74
Research And Development	20.97	22.34	25.56	31.16
Selling General And Administration	137.75	146.09	163.48	182.37
Normalized EBITDA	-66.69	-26.10	-15.70	42.33
Normalized Income	-92.08	-64.57	-56.47	0.55
Basic EPS	-0.70	-0.45	-0.37	0
Diluted EPS	-0.70	-0.45	-0.37	0
Tax Effect Of Unusual Items	-0.04	0.05	0.07	0
Tax Rate For Calcs	0.01	0.02	0.04	0
Total Unusual Items	-2.62	2.36	1.71	0
Total Unusual Items Excluding Goodwill	-2.62	2.36	1.71	0
Net Income From Continuing Operation Net Minority Interest	-94.66	-62.26	-54.84	0.55
Reconciled Depreciation	12.67	13.16	12.62	12.69
Reconciled Cost Of Revenue	20.81	26.33	35.05	40.72
Net Interest Income	-11.52	-21.86	-25.16	-24.34
Net Income From Continuing And Discontinued Operation	-94.66	-62.26	-54.84	0.55
Total Operating Income As Reported	-81.94	-44.01	-33.65	24.90
Diluted Average Shares	135.63	137.67	146.77	172.74
Basic Average Shares	135.63	137.67	146.77	160.43
Diluted NI Availto Com Stockholders	-94.66	-62.26	-54.84	0.55
Net Income Including Noncontrolling Interests	-94.66	-62.26	-54.84	0.55
Net Income Continuous Operations	-94.66	-62.26	-54.84	0.55
Other Income Expense	-2.62	2.36	1.71	0
Special Income Charges	-4.38	2.36	1.70	0
Other Special Charges	1.22	2.84	2.69	0
Restructuring And Mergern Acquisition	3.16	-5.20	-4.39	0
Gain On Sale Of Security	1.76	0	0.01	0
Net Non Operating Interest Income Expense	-11.52	-21.86	-25.16	-24.34
Total Other Finance Cost	0	0	2.69	0
Interest Expense Non Operating	14.10	26.61	30.48	29.08
Interest Income Non Operating	2.58	4.75	5.32	4.74
Depreciation Amortization Depletion Income Statement	10.84	10.84	10.84	10.84
Depreciation And Amortization In Income Statement	10.84	10.84	10.84	10.84
Amortization	10.84	10.84	10.84	10.84
Amortization Of Intangibles Income Statement	10.84	10.84	10.84	10.84
Operating Revenue	110.25	163.91	203.07	291.85

Peer Comparison

Healthcare sector peers, ranked by market cap

Company	Ticker	Market Cap	P/E	P/B	ROE	EV/EBITDA
Xeris Biopharma Holdings, Inc.this co.	XERS	$1.0B	-	73.41	4.0%	31.98
CareDx, Inc.	CDNA	$1.1B	-	3.49	-7.0%	-124.58
Teladoc Health, Inc.	TDOC	$1.1B	-	0.77	-14.5%	39.94
IRADIMED CORPORATION	IRMD	$1.1B	47.83	11.31	23.8%	37.30
The Pennant Group, Inc.	PNTG	$1.1B

Learn while you research

Hand-picked academy chapters to deepen your understanding of Xeris Biopharma Holdings, Inc. and the metrics that matter.

01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read 02 Growth Investing

Loading…

Year

Revenue

EBITDA

Net Profit

FCF

ROE

Rev Growth 1Y

NP Growth 1Y

2025

$292M

$42M

$1M

$28M

4.0%

43.7%

2024

$203M

$-14M

$-55M

$-38M

185.2%

23.9%

2023

$164M

$-24M

$-62M

$-49M

917.9%

48.7%

2022

$110M

$-69M

$-95M

$-103M

-209.5%

Metric

2022

2023

2024

2025

Total Revenue

110.25

163.91

203.07

291.85

Cost Of Revenue

22.63

28.64

36.83

42.57

Gross Profit

87.61

135.27

166.24

249.28

Operating Expense

169.55

179.28

199.88

224.38

Operating Income

-81.94

-44.01

-33.65

24.90

EBITDA

-69.31

-23.73

-13.99

42.33

EBIT

-81.98

-36.90

-26.62

29.64

Pretax Income

-96.08

-63.50

-57.10

0.55

Tax Provision

-1.42

-1.25

-2.27

Net Income

-94.66

-62.26

-54.84

0.55

Net Income Common Stockholders

-94.66

-62.26

-54.84

0.55

Total Expenses

192.19

207.92

236.72

266.95

Interest Expense

14.10

26.61

30.48

29.08

Interest Income

2.58

4.75

5.32

4.74

Research And Development

20.97

22.34

25.56

31.16

Selling General And Administration

137.75

146.09

163.48

182.37

Normalized EBITDA

-66.69

-26.10

-15.70

42.33

Normalized Income

-92.08

-64.57

-56.47

0.55

Basic EPS

-0.70

-0.45

-0.37

Diluted EPS

-0.70

-0.45

-0.37

Tax Effect Of Unusual Items

-0.04

0.05

0.07

Tax Rate For Calcs

0.01

0.02

0.04

Total Unusual Items

-2.62

2.36

1.71

Total Unusual Items Excluding Goodwill

-2.62

2.36

1.71

Net Income From Continuing Operation Net Minority Interest

-94.66

-62.26

-54.84

0.55

Reconciled Depreciation

12.67

13.16

12.62

12.69

Reconciled Cost Of Revenue

20.81

26.33

35.05

40.72

Net Interest Income

-11.52

-21.86

-25.16

-24.34

Net Income From Continuing And Discontinued Operation

-94.66

-62.26

-54.84

0.55

Total Operating Income As Reported

-81.94

-44.01

-33.65

24.90

Diluted Average Shares

135.63

137.67

146.77

172.74

Basic Average Shares

135.63

137.67

146.77

160.43

Diluted NI Availto Com Stockholders

-94.66

-62.26

-54.84

0.55

Net Income Including Noncontrolling Interests

-94.66

-62.26

-54.84

0.55

Net Income Continuous Operations

-94.66

-62.26

-54.84

0.55

Other Income Expense

-2.62

2.36

1.71

Special Income Charges

-4.38

2.36

1.70

Other Special Charges

1.22

2.84

2.69

Restructuring And Mergern Acquisition

3.16

-5.20

-4.39

Gain On Sale Of Security

1.76

0.01

Net Non Operating Interest Income Expense

-11.52

-21.86

-25.16

-24.34

Total Other Finance Cost

2.69

Interest Expense Non Operating

14.10

26.61

30.48

29.08

Interest Income Non Operating

2.58

4.75

5.32

4.74

Depreciation Amortization Depletion Income Statement

10.84

Depreciation And Amortization In Income Statement

10.84

Amortization

10.84

Amortization Of Intangibles Income Statement

10.84

Operating Revenue

110.25

163.91

203.07

291.85

Company

Ticker

Market Cap

P/E

P/B

ROE

EV/EBITDA

Xeris Biopharma Holdings, Inc.this co.

XERS

$1.0B

73.41

4.0%

31.98

CareDx, Inc.

CDNA

$1.1B

3.49

-7.0%

-124.58

Teladoc Health, Inc.

TDOC

$1.1B

0.77

-14.5%

39.94

IRADIMED CORPORATION

IRMD

$1.1B

47.83

11.31

23.8%

37.30

The Pennant Group, Inc.

PNTG

$1.1B

Xeris Biopharma Holdings, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Xeris Biopharma Holdings, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Key concepts to brush up on